259 results on '"De Benedetto, Anna"'
Search Results
2. Atopic Dermatitis (Eczema) Guidelines 2023: Highlights
3. Bleach baths enhance skin barrier, reduce itch but do not normalize skin dysbiosis in atopic dermatitis
4. History of S. aureus Skin Infection Significantly Associates with History of Eczema Herpeticum in Patients with Atopic Dermatitis
5. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE– and Institute of Medicine–based recommendations
6. CERS1 is a biomarker of Staphylococcus aureus abundance and atopic dermatitis severity
7. Whole genome sequencing identifies novel genetic mutations in patients with eczema herpeticum
8. Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials
9. Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials
10. Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following dupilumab treatment
11. Phenotypic and Endotypic Determinants of Atopic Dermatitis Severity From the Atopic Dermatitis Research Network (ADRN) Registry
12. Dietary Elimination for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis
13. Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis
14. Bleach baths for atopic dermatitis: A systematic review and meta-analysis including unpublished data, Bayesian interpretation, and GRADE
15. Skin barrier defects in atopic dermatitis: From old idea to new opportunity
16. Publisher Correction to: Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials
17. Polyphenol-Rich Cranberry Beverage Positively Affected Skin Health, Skin Lipids, Skin Microbiome, Inflammation, and Oxidative Stress in Women in a Randomized Controlled Trial.
18. Topical ruxolitinib 1.5% (JAK1/JAK2 inhibitor) improves clinical and patient‐reported outcomes in moderate to severe chronic hand dermatitis: Data from a small open‐label trial.
19. Peptides Derived from the Tight Junction Protein CLDN1 Disrupt the Skin Barrier and Promote Responsiveness to an Epicutaneous Vaccine
20. Editorial: A Successful Translational Story, from Scientific Discoveries to A Breakthrough Therapy for Atopic Dermatitis
21. Cutaneous Ceramide Synthase 1 (CERS1) Gene Expression is a Biomarker of Staphylococcus aureus Abundance and Severity of Atopic Dermatitis
22. Topical Treatments for Atopic Dermatitis: Systematic Review and Network Meta-Analysis of Randomized Trials
23. Extensive serum proteomics in Atopic Dermatitis Subjects reveals novel proteins and pathways relevant for severe disease
24. Systemic Treatments for Atopic Dermatitis: Systematic Review and Network Meta-Analysis of Randomized Trials
25. Patients with Atopic Dermatitis Colonized with Staphylococcus aureus Have a Distinct Phenotype and Endotype
26. Allergic Contact Dermatitis Due to Thiourea Derivatives in a Gun Holster
27. P03-011-23 Cranberry Juice Consumption Modulated Skin Lipids and Microbiome in a Randomized Controlled Trial
28. ISID1603 - Olink-based proteomics identifies new serum biomarkers associated with severe atopic dermatitis
29. ISID0930 - Staphylococcus aureus abundance is reduced in psoriasis compared with atopic dermatitis and does not associate with disease severity
30. ISID1599 - Rapid reduction in S. aureus in atopic dermatitis subjects following dupilumab treatment
31. Recalcitrant palmoplantar pustulosis controlled with dupilumab
32. Allergen Immunotherapy and Atopic Dermatitis: the Good, the Bad, and the Unknown
33. Erythema Multiforme Secondary to Poison Ivy Contact Dermatitis
34. Values and Preferences of Patients and Caregivers Regarding Treatment of Atopic Dermatitis (Eczema)
35. 339 Dupilumab 16-week efficacy and safety are robust and consistent in adults over 60 years of age with moderate-to-severe atopic dermatitis
36. 321 Cancer risk with topical pimecrolimus and tacrolimus for atopic dermatitis: systematic review and Bayesian meta-analysis
37. Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis
38. Allergen immunotherapy for atopic dermatitis: Systematic review and meta-analysis of benefits and harms
39. Onychomadesis and palmoplantar keratoderma associated with talquetamab therapy for relapsed and refractory multiple myeloma
40. Impact of Skin Biopsy and Clinical-Pathologic Correlation in Dermatology Inpatient Consults
41. Tight junction defects in patients with atopic dermatitis
42. Janus kinase inhibitors for treatment of morphea and systemic sclerosis: A literature review
43. Are skin microbes with lantibiotic biosynthesis genes reduced in atopic dermatitis subjects who are culture positive for Staphylococcus aureus?
44. Effect of Dupilumab on the Host-Microbe Interface in Atopic Dermatitis
45. Epidermal barrier proteins are significantly altered in psoriatic skin biopsies: 1986
46. Eruptive agminated nevi in a successfully treated Langerhans cell histiocytosis patient
47. Targetoid clinical morphology as a diagnostic clue of the lichenoid histopathologic subtype of pigmented purpuric dermatosis
48. Isotretinoin‐induced inflammation of the urethral meatus
49. Protease-Activated Receptor-2: investigating role in regulation of epidermal barrier and inflammation in Atopic Dermatitis based on skin type
50. Keratinocytes in Atopic dermatitis: Inflammatory signals
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.